Evaluate Revenue and Competitors
Estimated Revenue & Valuation
- Evaluate's estimated annual revenue is currently $33.9M per year.
- Evaluate received $Undisclosed in venture funding in November 2016.
- Evaluate's estimated revenue per employee is $150,500
- Evaluate's total funding is $42.9M.
Employee Data
- Evaluate has 225 Employees.
- Evaluate grew their employee count by -5% last year.
Evaluate's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Product Strategy and Management | Reveal Email/Phone |
2 | Head Delivery | Reveal Email/Phone |
3 | VP, Head Consulting & Analytics | Reveal Email/Phone |
4 | VP Product Platform | Reveal Email/Phone |
5 | VP, New Business Development | Reveal Email/Phone |
6 | VP, Strategic Accounts | Reveal Email/Phone |
7 | SVP, Sales and Account Management EMEA & APAC | Reveal Email/Phone |
8 | VP Market Engagement | Reveal Email/Phone |
9 | Head Engineering | Reveal Email/Phone |
10 | Head Business Intelligence | Reveal Email/Phone |
Evaluate Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.8M | 50 | 32% | N/A | N/A |
#2 | $1.4M | 16 | N/A | N/A | N/A |
What Is Evaluate?
Evaluate provides trusted commercial intelligence for the pharmaceutical industry. We help our clients to refine and transform their understanding of the past, present and future of the global pharmaceutical market to drive better decisions. Evaluate solutions give you the time and confidence to turn understanding into insight, and insight into action: EvaluatePharma - the trusted global view of the pharmaceutical market's past, present and future performance with consensus forecasts to 2024, company financials, pipelines, deals and more. @EvaluatePharma EvaluatePharma Vision - the first single view of the risk and reward of the R&D landscape with consensus forecasts, R&D costs at drug and trial level, success rates, predictive timelines and trial outcomes. EvaluateMedTech - tracks, benchmarks, and forecasts global performance for the medical device and diagnostic industry with consensus forecasts to 2024, company financials and more. Evaluate Custom Solutions - improve your strategic decision-making with customised solutions and deep insights that draw on our industry expertise and trusted commercial intelligence. Vantage - award-winning, thought-provoking news and insights into current and future developments in the industry, underpinned by Evaluate's commercial intelligence. Explore Evaluate at www.evaluate.com. Twitter: @Evaluatepharma, @Vantageanalysis Locations: Evaluate Global HQ: 11-29 Fashion Street London E1 6PX, UK Evaluate Americas EvaluatePharma USA Inc. 60 State Street, Suite 1910 Boston, MA 02109 Evaluate Asia Pacific Evaluate Japan KK Akasaka Garden City 4F 4-15-1 Akasaka, Minato-ku Tokyo 107-0052, Japan
keywords:N/A
$42.9M
Total Funding
225
Number of Employees
$33.9M
Revenue (est)
-5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Evaluate News
A group of tribal leaders from South Dakota visited a small museum in Barre, Massachusetts, to ask it to return the belongings of their...
Today in our next installment of "Three and Out," we give some early thoughts and takes on the spring evaluation period.
Much of the team is expected to be back in the fall when training camp begins. The final two weeks present an opportunity to finish off an impressive run...
Every company on this list of the top 10 2019 marketing launches — compiled by Evaluate in January — has a lot to prove. We have Alexion, trying to safeguard its big moneymaking franchise, topping the chart. Novartis and its new CEO are the dominant player this year, with 3 top contenders for ...
Evaluate Ltd., a London, UK-based provider of commercial intelligence and predictive analytics to the pharmaceutical industry, completed an acquisition of Black Swan Analysis, a London, UK-based consultancy specializing in asset valuations and epidemiology. The amount of the deal was not disclo ...
Other Companies in LONDON
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $35.9M | 225 | 3% | N/A |
#2 | $35.9M | 225 | -29% | N/A |
#3 | $35.9M | 225 | 8% | N/A |
#4 | $66.8M | 225 | 3% | N/A |
#5 | $71.8M | 225 | -3% | N/A |
Evaluate Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2016-11-09 | $Undisclosed | Undisclosed | HgCapital | Article |